{"id":"NCT02408523","sponsor":"UCB BIOSCIENCES, Inc.","briefTitle":"A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications","officialTitle":"A Double-blind, Randomized, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04","primaryCompletion":"2019-04","completion":"2019-06","firstPosted":"2015-04-03","resultsPosted":"2020-04-16","lastUpdate":"2020-12-17"},"enrollment":242,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Lacosamide Tablet","otherNames":["Vimpat"]},{"type":"DRUG","name":"Lasosamide Oral Solution","otherNames":["Vimpat"]},{"type":"OTHER","name":"Placebo Tablet","otherNames":[]},{"type":"OTHER","name":"Placebo Oral Solution","otherNames":[]}],"arms":[{"label":"Lacosamide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Evaluating efficacy \\& safety of lacosamide versus Placebo in a blinded fashion as add-on Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject 4 years of age or greater with idiopathic generalized epilepsy currently taking 1 to 3 antiepileptic drugs. Maximum duration of study drug administration is 28 weeks. Eligible subjects may choose to enter the open-label extension study after completion.","primaryOutcome":{"measure":"Time to the Second Primary Generalized Tonic Clonic (PGTC) Seizure During the 24-week Treatment Period From Visit 2 (Week 0) to Visit 10 (Week 24)","timeFrame":"During the Treatment Period from Visit 2 (Week 0) to Visit 10 (Week 24)","effectByArm":[{"arm":"Placebo (FAS)","deltaMin":76,"sd":null},{"arm":"Lacosamide (FAS)","deltaMin":49,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":115,"countries":["United States","Australia","Belgium","Brazil","Bulgaria","China","Czechia","France","Germany","Hungary","Israel","Italy","Japan","Mexico","Poland","Portugal","Romania","Russia","Slovakia","South Korea","Spain","Taiwan"]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":121},"commonTop":["Dizziness","Somnolence","Headache","Nausea","Fatigue"]}}